Key result
Duett vascular closure device achieves successful standalone hemostasis in ~98% of patients.
Answers are grounded in this paper and cite their sources.
The aim of this first U.S. feasibility study was to investigate the safety and efficacy of a novel vascular sealing device, Duett, following percutaneous endovascular procedures. Immediately following a catheterization procedure, the sealing device was deployed at the femoral arterial access site in 43 patients (diagnostic 29, intervention 11, intervention + abciximab 3). Patients were followed up at 1 month with clinical assessment, ankle-brachial index measurement, and Doppler ultrasound of the treated femoral artery puncture site. Successful hemostasis was achieved with the Duett alone in 42/43 (97.7%) patients. There was one uncomplicated crossover to manual compression. The time to hemostasis was 4.0+/-1.5, 6.9+/-4.2, and 5.8+/-1.2 min for diagnostic, interventional, and abciximab patients, respectively. At 1-month follow-up, one patient (2.3%) required ultrasound-guided compression for treatment of a pseudoaneurysm. There were no other major complications. This novel vascular sealing device appears to achieve rapid and safe hemostasis successfully immediately following a wide range of percutaneous endovascular procedures.
No takes yet. Share an insight, caveat, or question.
Mooney et al. (2000) studied Femoral arterial access site closure following percutaneous endovascular procedures (cardiac catheterization and coronary interventions) (n=43). Duett vascular closure device was evaluated on Successful hemostasis. The Duett vascular closure device achieved successful hemostasis alone in 97.7% (42/43) of patients with a 2.3% rate of pseudoaneurysm at 1 month.
Synapse has enriched 10 related papers. Consider them for comparative context: